Non-compliance of norms: USFDA recommends action against Strides Pharma Puducherry facility

Strides Pharma has received a communication from the US Food and Drug Administration (USFDA) on May 4, 2019, classifying the facility as OAI based on the inspection conducted from January 28 to February 5, 2019.

New Delhi: Strides Pharma Science Ltd Monday said the US health regulator has classified its Puducherry facility as official action initiated (OAI) for non-compliance of norms following an inspection.

The company has received a communication from the US Food and Drug Administration (USFDA) on May 4, 2019, classifying the facility as OAI based on the inspection conducted from January 28 to February 5, 2019, Strides Pharma Science said in a regulatory filing.

According to the USFDA, an OAI means regulatory and/or administrative actions will be recommended for the facility which was inspected after it determines if the areas evaluated were in compliance with applicable laws and regulations.

Also Read: Strides Pharma gets USFDA approval for Oral Dosage facility in Singapore

"While the company is disappointed with the outcome of the inspection, the company believes that the classification will not have an impact on the current supplies and revenues from the facility," Strides Pharma Sciences said.

It, however, said of the 34 ANDA's (abbreviated new drug application) pending approval, Puducherry has 10 ANDA's where the company expects delays until the facility is reclassified.

Also Read: Strides to exit investment in Arrow Pharma for over Rs 2000 crore